PrecivityAD2
An advanced blood-based diagnostic assessment that analyses key biomarkers associated with Alzheimer’s disease, including indicators linked to amyloid plaques and tau pathology. Combined with expert clinical interpretation, it provides a clear, evidence-based indication of risk to support earlier and more accurate decision-making.
For whom
Individuals experiencing memory concerns or cognitive changes, as well as those seeking early, proactive insight into their brain health.
What
A high-quality, clinically validated diagnostic assessment that evaluates key biomarkers associated with Alzheimer’s disease.
How
Using a simple blood sample, combined with advanced analysis and expert clinical interpretation, to generate a clear and personalised result.
Why
To enable earlier detection, reduce uncertainty, and support more informed decisions about care, treatment, and next steps.
